George M. Milne Jr. - 31 Dec 2022 Form 5 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney-in-Fact
Issuer symbol
AMLX
Transactions as of
31 Dec 2022
Net transactions value
$0
Form type
5
Filing time
14 Feb 2023, 15:35:32 UTC
Previous filing
10 Jun 2022
Next filing
06 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Conversion of derivative security +689,425 +311% 910,821 06 Jan 2022 Direct F1
transaction AMLX Common Stock Gift $0 -13,800 -1.5% $0.000000 897,021 29 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Series A Preferred Stock Conversion of derivative security $0 -262,282 -100% $0.000000* 0 06 Jan 2022 Common Stock 262,282 Direct F1
transaction AMLX Series B Preferred Stock Conversion of derivative security $0 -384,449 -100% $0.000000* 0 06 Jan 2022 Common Stock 384,449 Direct F1
transaction AMLX Series C-1 Preferred Stock Conversion of derivative security $0 -19,482 -100% $0.000000* 0 06 Jan 2022 Common Stock 19,482 Direct F1
transaction AMLX Series C-2 Preferred Stock Conversion of derivative security $0 -23,212 -100% $0.000000* 0 06 Jan 2022 Common Stock 23,212 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.